Cargando…
Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: A randomized, crossover study
AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solution (TIS) using the I‐neb device to the standard PARI‐LC Plus nebulizer in children with cystic fibrosis. METHODS: A randomized, open‐label, crossover study was performed. In 2 separate study visits,...
Autores principales: | van Velzen, Annelies J., Uges, Joris W.F., Heijerman, Harry G.M., Arets, Bert G.M., Nuijsink, Marianne, van der Wiel‐Kooij, Els C., van Maarseveen, Erik M., van Zanten, Gijsbert A., Pullens, Bas, Touw, Daan J., Janssens, Hettie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710527/ https://www.ncbi.nlm.nih.gov/pubmed/31112621 http://dx.doi.org/10.1111/bcp.13988 |
Ejemplares similares
-
Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019) -
Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules(®) for exacerbations in patients with COPD: Historical cohort study
por: Price, David B., et al.
Publicado: (2018) -
CFTR Modulators: Does One Dose Fit All?
por: van der Meer, Renske, et al.
Publicado: (2021) -
Ease of use of tobramycin inhalation powder compared with nebulized
tobramycin and colistimethate sodium: a crossover study in cystic fibrosis
patients with pulmonary Pseudomonas aeruginosa
infection
por: Greenwood, James, et al.
Publicado: (2017) -
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)